Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Brainstorm Cell Therapeutics Inc. (BCLI : NSDQ)
 
 • Company Description   
BrainStorm Cell Therapeutics Inc. is a biotechnology company. It develops autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis, Multiple Sclerosis and Parkinson's disease. Brainstorm Cell Therapeutics is based in New York.

Number of Employees: 40

 
 • Price / Volume Information   
Yesterday's Closing Price: $3.33 Daily Weekly Monthly
20 Day Moving Average: 374,124 shares
Shares Outstanding: 36.28 (millions)
Market Capitalization: $120.81 (millions)
Beta: -0.09
52 Week High: $8.14
52 Week Low: $2.75
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 10.63% 14.08%
12 Week 0.00% -0.99%
Year To Date -26.41% -36.89%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
1325 AVENUE OF AMERICAS 28TH FLOOR
-
NEW YORK,NY 10019
USA
ph: 201-488-0460
fax: -
cdavis@lifesciadvisors.com http://www.brainstorm-cell.com
 
 • General Corporate Information   
Officers
Chaim Lebovits - Chief Executive Officer
Preetam Shah - Chief Financial Officer
Irit Arbel - Director
June S. Almenoff - Director
Jacob Frenkel - Director

Peer Information
- (-)
- (-)
- (-)
- (-)
- (-)
- (-)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 10501E201
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 09/01/21
Next Expected EPS Date: 02/03/22
Share - Related Items
Shares Outstanding: 36.28
Most Recent Split Date: 9.00 (0.07:1)
Beta: -0.09
Market Capitalization: $120.81 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $-0.22 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-0.74 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 02/03/22  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 4.85
Price/Cash Flow: -
Price / Sales: -
EPS Growth
vs. Year Ago Period: -7.14%
vs. Previous Quarter: 11.76%
Sales Growth
vs. Year Ago Period: -%
vs. Previous Quarter: -%
ROE
09/30/21 - -94.92
06/30/21 - -91.49
03/31/21 - -113.00
ROA
09/30/21 - -68.14
06/30/21 - -66.91
03/31/21 - -80.03
Current Ratio
09/30/21 - 4.78
06/30/21 - 4.37
03/31/21 - 5.01
Quick Ratio
09/30/21 - 4.78
06/30/21 - 4.37
03/31/21 - 5.01
Operating Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Net Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Pre-Tax Margin
09/30/21 - -
06/30/21 - -
03/31/21 - -
Book Value
09/30/21 - 0.69
06/30/21 - 0.83
03/31/21 - 1.00
Inventory Turnover
09/30/21 - -
06/30/21 - -
03/31/21 - -
Debt-to-Equity
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
Debt-to-Capital
09/30/21 - 0.00
06/30/21 - 0.00
03/31/21 - 0.00
 

Powered by Zacks Investment Research ©